A Study to Desensitize Allergic Reactions to Treatments for Blood Disorders

Titre officiel

Desensitization of Immunomodulating Agent-Related Hypersensitivity Reactions as a Means to Provide Therapeutic Options in the Management of Plasma Cell Disorders (DeHyperPCD)

Sommaire:

Les patients atteints de myélome multiple (un type de cancer du sang touchant les globules blancs) ou d’amylose (accumulation anormale d’une protéine appelée amyloïde dans l’organisme) reçoivent souvent un traitement avec les médicaments lénalidomide ou pomalidomide. Certains patients peuvent avoir une réaction allergique à ces médicaments, ce qui signifierait l’arrêt du traitement. L’objectif de cette étude est de voir dans quelle mesure la désensibilisation est sûre et utile pour permettre aux patients de recevoir un traitement supplémentaire avec la lénalidomide ou la pomalidomide.

Description de l'essai

Primary Outcome:

• Number of participants successfully completing desensitization program

Secondary Outcome:

• Distress Assessment and Response Tool (DART) score
• Edmonton Symptom Assessment System (ESAS) score
• Frequency of interrupted treatment with immunomodulating agent
• Duration of interrupted treatment with immunomodulating agent
• Mortality rate associated with disease progression or treatment-related toxicity
• Frequency of rash recurrence
• Duration of treatment with immunomodulating agent post desensitization
• Incidence of adverse events during desensitization procedures and hospital stay
• Total duration of treatment with immunomodulating agent
• Duration of treatment with supportive care agents

Some doctors believe that the body may be taught to react less or stop reacting to, the things that would otherwise trigger an allergic reaction. This is called desensitization. Desensitization is usually done with repeat exposure to the thing that causes the allergic reaction. For example, people who have allergies may receive small, controlled doses of the allergen over a period of time until the allergic reactions are tolerable or are stopped completely. The researchers want to see if giving low doses of lenalidomide or pomalidomide to people who experienced an allergic reaction to these medications can become desensitized so that they are able to continue treatment for their disease with these drugs.

Voir cet essai sur ClinicalTrials.gov